The efficacy and six-week tolerability of Simvastatin 80 and 160 mg/day
The efficacy and six-week tolerability of Simvastatin 80 and 160 mg/day
复制标题
DOI：
10.1016/s0002-9149(96)00742-4
复制
发表时间：
1997-01-01
影响因子：
2.8
通讯作者：
Tobert, JA
中科院分区：
文献类型：
--
作者：
Davidson, MH;Stein, EA;Tobert, JA
羟甲基戊二酰辅酶A还原酶抑制剂辛伐他汀是目前批准的最有效的降血脂药物，并已被证明可以降低冠状动脉疾病患者的死亡率和冠状动脉发病率。对于这些患者，美国国家胆固醇教育计划提倡将低密度脂蛋白（LDL）胆固醇降至160 mg/dl，甘油三酯（TG）降至正常上限的3倍。未观察到新的或非预期的不良反应。我们的结论是，辛伐他汀在80和160毫克/天的剂量提供了额外的疗效与低的短期不良反应的发生率，我们的研究结果支持继续调查辛伐他汀在这些剂量。(C)1997年，Excerpta Medica，Inc.
The hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin is the most effective of the currently approved hypolipidemic drugs and has been shown to reduce mortality and coronary morbidity in patients with coronary artery disease. For these patients the United States National Cholesterol Education Program advocates reducing low-density lipoprotein (LDL) cholesterol to 160 mg/dl and triglycerides (TG) 3 times the upper limit of normal. No new or unexpected adverse effects were observed. We conclude that simvastatin at doses of 80 and 160 mg/day provides additional efficacy with a low short-term incidence of adverse effects; our results support the continued investigation of simvastatin at these doses. (C) 1997 by Excerpta Medica, Inc.